CD16⁺NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.

Survival was improved in the treatment group (26-48 days) to near statistical significance ( P =0.0566), but all mice ultimately succumbed to disease ( Figure 5B ).

also in 222 other papers